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Background
Pancreatoduodenectomy or Whipple's procedure is still
the treatment of choice for periampulary and head of pan-
creas tumors, as well as distal coledochal neoplasms. The
effectiveness of this procedure is related to the clinical
stage of the disease, the conditions of the patient in addi-
tion to the experience and the skill of the surgical institu-
tional equipment. The objective was to evaluate
morbidity and mortality after the accomplishment of
Whipple's technique.
Materials and methods
A retrospective analysis was performed with the database
of patients submitted to Whipple's procedure from Janu-
ary 1990 to May 2006 in the Instituto Nacional de Can-
cerología.
Results
From 69 patients submitted to surgery, 35 were women
(%) and 34 men (%). the average age at the time of diag-
nosis was 52.8 years (rank 18–73). Out of 69 patients 59
had a neoplasm of the biliary three, finding 23 pancreatic
tumors (%), 25 of Vater's ampula (37.5%) 8 of the duo-
denum (12.5%) and 3 coledochal tumors (%). We also
found two patients with neuroendocrine tumors, four
patients with Papillary and cystic tumors of the pancreas,
one patient with an adenoma of Vater's ampula and three
patients with chronic pancreatitis. In 7 patients pylorus
preservation surgery was carried out (10.93%), in the rest
classic Whipple was performed (87.5%). Average surgery
time was 7 hours and 20 min, with an average bleeding
time of 1293 ml (200–6000). The average hospital stay
was 21 days, only 3 patients did not require ICU. Fourteen
patients developed abdominal sepsis (18.2%), thirteen
suffered respiratory complications (nosocomial pneumo-
nia, pulmonary embolism) (20.31%), nine patients pre-
sented biliary fistula (14.06%) and eight more an
intestinal fistula (12.5%). Twenty patients received adju-
vant treatment for the neoplasm in turn (31.25%). Of 18
patients who developed recurrence of the disease
(28.12%), 10 presented local disease. After a median fol-
low up of 18 months, 22 patients are alive (34,37%) 13 of
which was alive without evidence of disease. We splitted
the series into two different periods of 7.5 years each. Dur-
ing the first period (January 1990–June 1997) 18 classic
Whipple's surgery and one pylorus preservation surgery
were performed; we had a morbidity of 52,63% and a
mortality of 31,57% (6 patients). During the second
period (July 1997–September of the 2005) 44 patients
were submitted to classic Whipple and 6 patients to
pylorus preservation surgery; with a morbidity of 35,3%
(16 patients) and a mortality of 8%.
Conclusion
Pancreatoduodenectomy is the election procedure for
patients with pancreatobiliary tumors. In spite of the
advances and variations to the technique, it remains a
hazardous procedure. Surgery outcome is importantly
related with the greater training and experience of the sur-
gical team as we observed in our series.
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